Inveniam Group
Inveniam is a boutique consulting firm founded in 2013, with headquarters in Barcelona, Spain, and additional operations in Israel. The firm specializes in transaction and strategy advisory services, focusing on technology-based deals in life sciences and resource sustainability. Inveniam assists a diverse range of clients, including start-ups, researchers, corporations, and public institutions, throughout the entire deal life cycle. Their services encompass opportunity scouting, assessment, commercialization, deal structuring, and closing. With a team that brings together various expertise and industry insights, Inveniam aims to bridge the gap between technology originators and the market, providing specialized support that enhances the potential of technology ventures. The firm's global reach is strengthened through strategic alliances and collaborations.
2 past transactions
Nimble Diagnostics
Venture Round in 2023
Nimble Diagnostics is a company that offers a range of DNA testing services, including paternity testing, prenatal gender testing, family relationship testing, ancestry DNA testing, and DNA art. In addition to these services, the company provides cancer nutraceuticals, aiming to support patients' health and well-being. Nimble Diagnostics leverages the internet to deliver its offerings globally at affordable prices, maintaining a commitment to accessible molecular diagnostics. The company also focuses on developing medical monitoring devices that enhance patient care, particularly for individuals with medical implants. These devices enable continuous, non-invasive monitoring, allowing healthcare providers to transition from reactive to proactive care, thereby reducing clinical complications associated with implanted stents.
AtG Therapeutics
Seed Round in 2022
AtG Therapeutics is a Barcelona-based biotechnology company spun off from IDIBELL and ICO. It focuses on developing innovative drug classes and biomarkers aimed at preventing cancer therapeutic resistance. The company's mission is to discover and advance new therapeutic technologies, including biomarkers, drugs, and novel mechanisms, enabling healthcare professionals to enhance the lives of patients affected by cancer therapeutic resistance.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.